Search Results
You are looking at 1 - 1 of 1 items for
- Author: A E Michael x
- Refine by access: Open Access content only x
VCA Colonial Animal Hospital, Ithaca, New York, USA
Search for other papers by Michael Merkhassine in
Google Scholar
PubMed
Weill Cornell College of Medicine, New York, New York, USA
Search for other papers by Reilly W Coch in
Google Scholar
PubMed
Search for other papers by Carol E Frederick in
Google Scholar
PubMed
Search for other papers by Lucinda L Bennett in
Google Scholar
PubMed
Fate Therapeutics, San Diego, California, USA
Search for other papers by Seth A Peng in
Google Scholar
PubMed
Search for other papers by Benjamin Morse in
Google Scholar
PubMed
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
Search for other papers by Bethany P Cummings in
Google Scholar
PubMed
Search for other papers by John P Loftus in
Google Scholar
PubMed
Glucagon plays a central role in amino acid (AA) homeostasis. The dog is an established model of glucagon biology, and recently, metabolomic changes in people associated with glucagon infusions have been reported. Glucagon also has effects on the kidney; however, changes in urinary AA concentrations associated with glucagon remain under investigation. Therefore, we aimed to fill these gaps in the canine model by determining the effects of glucagon on the canine plasma metabolome and measuring urine AA concentrations. Employing two constant rate glucagon infusions (CRI) – low-dose (CRI-LO: 3 ng/kg/min) and high-dose (CRI-HI: 50 ng/kg/min) on five research beagles, we monitored interstitial glucose and conducted untargeted liquid chromatography–tandem mass spectrometry (LC-MS/MS) on plasma samples and urine AA concentrations collected pre- and post-infusion. The CRI-HI induced a transient glucose peak (90–120 min), returning near baseline by infusion end, while only the CRI-LO resulted in 372 significantly altered plasma metabolites, primarily reductions (333). Similarly, CRI-HI affected 414 metabolites, with 369 reductions, evidenced by distinct clustering post-infusion via data reduction (PCA and sPLS-DA). CRI-HI notably decreased circulating AA levels, impacting various AA-related and energy-generating metabolic pathways. Urine analysis revealed increased 3-methyl-l-histidine and glutamine, and decreased alanine concentrations post-infusion. These findings demonstrate glucagon’s glucose-independent modulation of the canine plasma metabolome and highlight the dog’s relevance as a translational model for glucagon biology. Understanding these effects contributes to managing dysregulated glucagon conditions and informs treatments impacting glucagon homeostasis.